A reciprocal relationship exists between non-steroidal anti-inflammatory drug-activated gene-1 (NAG-1) and

Related Experiment Videos

Genzo Iguchi1, Kali Chrysovergis, Seong-Ho Lee

  • 1Laboratory of Molecular Carcinogenesis, National Institute of Environmental Health Sciences, National Institutes of Health, 111 T.W. Alexander Drive, RTP, NC 27709, USA.

Cancer Letters
|April 21, 2009
PubMed

Insights

Investigating non-steroidal anti-inflammatory drug (NSAID)-activated gene-1 (NAG-1) and COX-2 in colon tissue revealed an inverse relationship. Tumor tissue showed reduced NAG-1 and increased COX-2, suggesting a role in colon tumorigenesis.

Area of Science:

  • Molecular biology
  • Oncology
  • Biochemistry

Background:

  • Non-steroidal anti-inflammatory drug (NSAID)-activated gene-1 (NAG-1) and cyclooxygenase-2 (COX-2) are implicated in inflammation, apoptosis, and cancer development.
  • Understanding the interplay between NAG-1 and COX-2 is crucial for comprehending tumorigenesis, particularly in colon tissue.

Purpose of the Study:

  • To investigate the relationship between NAG-1 and COX-2 expression in normal and tumor tissues.
  • To explore the influence of prostaglandin E2 (PGE2) and celecoxib (Celebrex) on NAG-1 expression.

Main Methods:

  • Comparative analysis of NAG-1 and COX-2 expression in human tumor and normal tissues.
  • Examination of gene expression in Apc(Min/+) and COX-2(-/-) mouse models.
  • In vitro experiments assessing the effects of PGE2 and celecoxib on NAG-1 levels.

Main Results:

  • COX-2 expression was significantly elevated in tumor tissues compared to normal tissues.
  • NAG-1 expression was notably decreased in tumor tissues.
  • Prostaglandin E2 (PGE2) treatment led to a reduction in NAG-1 expression, while celecoxib (Celebrex) induced NAG-1 expression.

Conclusions:

  • A potential inverse correlation exists between NAG-1 and COX-2 expression during colon tumor formation.
  • These findings suggest that targeting the COX-2 pathway may influence NAG-1 levels, impacting colon cancer progression.

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
Gastritis-II: Pathophysiology01:17

Gastritis-II: Pathophysiology

Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
Inflammatory Response01:28

Inflammatory Response

An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammatory Bowel Disease III: Crohn's Disease01:25

Inflammatory Bowel Disease III: Crohn's Disease

Crohn’s disease is a chronic, relapsing form of inflammatory bowel disease characterized by segmental, transmural inflammation that can affect any part of the gastrointestinal tract. Its pathogenesis arises from a combination of genetic susceptibility, environmental exposures, epithelial barrier dysfunction, and immune dysregulation. Together, these factors lead to an exaggerated immune response against components of the gut microbiome.Genetic and Environmental InfluencesMultiple genetic...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...